CCA
GBT

Column Capital Advisors’s Global Blood Therapeutics, Inc. GBT Stock Holding History

Column Capital Advisors’s Portfolio GBT Stock Details GBT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-40
Closed -$3K – 813
2019
Q4 		$3K Buy
+40
New +$2.37K ﹤0.01% 594

Other funds holding GBT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Column Capital Advisors's GBT Position: Q1 2020 in Review

Column Capital Advisors sold out of Global Blood Therapeutics, Inc. (GBT) in Q1 2020, closing a stake of 40 shares — an estimated $3K sold.

Column Capital Advisors first reported a position in GBT in Q4 2019 and held it in 1 quarter. The position peaked at $3K in Q4 2019. 220 funds tracked by Wall St. Rank hold GBT as of Q1 2020.

  • Column Capital Advisors reported no remaining Global Blood Therapeutics, Inc. position as of Q1 2020 after selling out during the quarter.
  • Column Capital Advisors sold 40 Global Blood Therapeutics, Inc. shares in Q1 2020, an estimated $3K.
  • Column Capital Advisors first reported a position in Global Blood Therapeutics, Inc. in Q4 2019 and held it in 1 quarter.
  • Column Capital Advisors's Global Blood Therapeutics, Inc. position peaked at $3K in Q4 2019.
  • 220 funds tracked by Wall St. Rank held Global Blood Therapeutics, Inc. as of Q1 2020.

Based on Column Capital Advisors's 13F filing for Q1 2020, filed 11 May 2020.